Skip to content

Total debt at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$20.04M+211%
Arrowhead Research logo
Arrowhead ResearchARWR
$107.88M-5.6%
Eli Lilly logo
Eli LillyLLY
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
AbbVie logo
AbbVieABBV
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $8.05M.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s total debt?
Apogee Therapeutics, Inc. (APGE) reported total debt of $8.05M in Q1 2026.
How has Apogee Therapeutics, Inc.'s total debt changed year-over-year?
Apogee Therapeutics, Inc.'s total debt decreased by 31.9% year-over-year, from $11.82M to $8.05M.
What is the long-term trend for Apogee Therapeutics, Inc.'s total debt?
Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s total debt has grown at a 110.3% compound annual growth rate (CAGR), from $2M to $8.85M.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.